What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?
AIDS Serodiagnosis
Adolescent
Adult
Anti-HIV Agents
/ therapeutic use
Botswana
/ epidemiology
Epidemics
/ prevention & control
Female
HIV Infections
/ drug therapy
Humans
Incidence
Kenya
/ epidemiology
Male
Mass Screening
Prevalence
Public Health
South Africa
/ epidemiology
Time-to-Treatment
Uganda
/ epidemiology
Viral Load
Zambia
/ epidemiology
HIV care continuum
HIV elimination
HIV prevention
HIV testing
antiretroviral therapy
public health
universal access
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
17
10
2019
accepted:
14
01
2020
entrez:
25
2
2020
pubmed:
25
2
2020
medline:
5
11
2020
Statut:
ppublish
Résumé
Achieving HIV epidemic control globally will require new strategies to accelerate reductions in HIV incidence and mortality. Universal test and treat (UTT) was evaluated in four randomized population-based trials (BCPP/Ya Tsie, HPTN 071/PopART, SEARCH, ANRS 12249/TasP) conducted in sub-Saharan Africa (SSA) during expanded antiretroviral treatment (ART) eligibility by World Health Organization guidelines and the UNAIDS 90-90-90 campaign. These three-year studies were conducted in Botswana, Zambia, Uganda, Kenya and South Africa in settings with baseline HIV prevalence from 4% to 30%. Key observations across studies were: (1) Universal testing (implemented via a variety of home and community-based testing approaches) achieved >90% coverage in all studies. (2) When coupled with robust linkage to HIV care, rapid ART start and patient-centred care, UTT achieved among the highest reported population levels of viral suppression in SSA. Significant gains in population-level viral suppression were made in regions with both low and high baseline population viral load; however, viral suppression gains were not uniform across all sub-populations and were lower among youth. (3) UTT resulted in marked reductions in community HIV incidence when universal testing and robust linkage were present. However, HIV elimination targets were not reached. In BCPP and HPTN 071, annualized HIV incidence was approximately 20% to 30% lower in the intervention (which included universal testing) compared to control arms (no universal testing). In SEARCH (where both arms had universal testing), incidence declined 32% over three years. (4) UTT reduced HIV associated mortality by 23% in the intervention versus control communities in SEARCH, a study in which mortality was comprehensively measured. These trials provide strong evidence that UTT inclusive of universal testing increases population-level viral suppression and decreases HIV incidence and mortality faster than the status quo in SSA and should be adapted at a sub-country level as a public health strategy. However, more is needed, including integration of new prevention interventions into UTT, in order to reach UNAIDS HIV elimination targets.
Identifiants
pubmed: 32091179
doi: 10.1002/jia2.25455
pmc: PMC7038879
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25455Subventions
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Organisme : CGH CDC HHS
ID : U01 GH000447
Pays : United States
Organisme : CGH CDC HHS
ID : U2G GH001911
Pays : United States
Organisme : PEPFAR
Pays : United States
Informations de copyright
© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Lancet. 2010 Aug 14;376(9740):532-9
pubmed: 20638713
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Lancet. 2010 Jun 12;375(9731):2092-8
pubmed: 20537376
N Engl J Med. 2019 Jul 18;381(3):219-229
pubmed: 31314966
J Int AIDS Soc. 2016 Jun 01;19(1):20913
pubmed: 27258430
PLoS One. 2019 Jan 23;14(1):e0210126
pubmed: 30673744
Curr Opin HIV AIDS. 2018 May;13(3):170-178
pubmed: 29432227
Am J Public Health. 2013 Jun;103(6):e14-23
pubmed: 23597344
J Acquir Immune Defic Syndr. 2016 Nov 01;73(3):e39-e45
pubmed: 27741031
N Engl J Med. 2019 Jul 18;381(3):207-218
pubmed: 31314965
Lancet HIV. 2018 Mar;5(3):e116-e125
pubmed: 29199100
N Engl J Med. 2019 Jul 18;381(3):230-242
pubmed: 31314967
PLoS One. 2010 Jun 10;5(6):e11068
pubmed: 20548786
N Engl J Med. 2019 May 23;380(21):1985-1987
pubmed: 31042822
BMJ Glob Health. 2019 Feb 21;4(1):e001522
pubmed: 30899569
Lancet. 2009 Jan 3;373(9657):48-57
pubmed: 19038438
AIDS. 2014 Jan 14;28(2):227-33
pubmed: 24413310
J Int AIDS Soc. 2018 Jan;21(1):
pubmed: 29314658
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
Lancet HIV. 2016 Mar;3(3):e111-9
pubmed: 26939734
AIDS Behav. 2019 Apr;23(4):929-946
pubmed: 30415432
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
Lancet. 2018 Jul 28;392(10144):312-358
pubmed: 30032975
BMC Public Health. 2018 May 29;18(1):668
pubmed: 29843667
AIDS. 2018 Sep 24;32(15):2179-2188
pubmed: 30134294